187 Participants Needed

Elranatamab for Multiple Myeloma

Recruiting at 113 trial locations
PC
Overseen ByPfizer CT.gov Call Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

This trial is testing Elranatamab, a drug that helps the immune system target and kill cancer cells, in patients with a type of blood cancer that hasn't responded to other treatments. The drug works by connecting immune cells to cancer cells so they can be destroyed.

Do I need to stop my current medications for the trial?

The trial information does not specify if you need to stop taking your current medications. However, it mentions that you should not have taken an investigational drug within 30 days before starting the trial.

What data supports the effectiveness of the drug Elranatamab for treating multiple myeloma?

Elranatamab has shown promising results in treating multiple myeloma, with a study reporting a 63.6% response rate and 38.2% of patients achieving complete response or better. The drug was effective even in patients who had received prior treatments, with a median duration of response of 17.1 months and manageable safety profile.12345

Is Elranatamab safe for humans?

In a clinical trial for multiple myeloma, Elranatamab was found to have manageable safety with no dose-limiting toxicities observed. Some patients experienced side effects like low blood cell counts (cytopenias) and a reaction called cytokine release syndrome, but these were considered manageable.12467

What makes the drug Elranatamab unique for treating multiple myeloma?

Elranatamab is unique because it is a bispecific antibody that targets both BCMA on myeloma cells and CD3 on T cells, activating the T cells to attack the cancer cells. It is administered subcutaneously and has shown promising results in patients who have already undergone multiple other treatments, including those who have had prior BCMA-directed therapy.12489

Research Team

PC

Pfizer CT.gov Call Center

Principal Investigator

Pfizer

Eligibility Criteria

This trial is for adults with multiple myeloma who haven't responded to at least one proteasome inhibitor (PI), one immunomodulatory drug (IMiD), and one anti-CD38 antibody. Participants should have measurable disease, be in stable condition, not pregnant, willing to use contraception, and without other active cancers or serious infections. There are two groups: those who've had BCMA-targeted therapy before and those who haven't.

Inclusion Criteria

Not pregnant and willing to use contraception
I have been diagnosed with multiple myeloma.
Any side effects from my previous treatments have mostly gone away.
See 11 more

Exclusion Criteria

Previous administration with an investigational drug within 30 days or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer)
I had a stem cell transplant less than 3 months ago.
I have been diagnosed with amyloidosis.
See 5 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive Elranatamab monotherapy to evaluate clinical benefit in relapsed/refractory multiple myeloma

16 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Long-term follow-up

Participants are monitored for progression-free survival and overall survival

up to approximately 20.14 months

Treatment Details

Interventions

  • Elranatamab (PF-06863135)
Trial OverviewThe study tests Elranatamab as a single treatment for relapsed/refractory multiple myeloma. It's a bispecific antibody that directs the body's T-cells to attack the cancer cells by recognizing both T-cell markers (CD3) and myeloma cell markers (BCMA). The goal is to see if this targeted approach can help control the disease.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Elranatamab (cohort B)Experimental Treatment1 Intervention
BCMA-CD3 bispecific antibody
Group II: Elranatamab (cohort A)Experimental Treatment1 Intervention
BCMA-CD3 bispecific antibody

Find a Clinic Near You

Who Is Running the Clinical Trial?

Pfizer

Lead Sponsor

Trials
4,712
Recruited
50,980,000+
Known For
Vaccine Innovations
Top Products
Viagra, Zoloft, Lipitor, Prevnar 13

Albert Bourla

Pfizer

Chief Executive Officer since 2019

PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki

Patrizia Cavazzoni profile image

Patrizia Cavazzoni

Pfizer

Chief Medical Officer

MD from McGill University

Findings from Research

Elranatamab is a bispecific T cell engager that targets BCMA on multiple myeloma cells, effectively activating T cells to kill these cancer cells, and has received its first approval in the USA for treating adult patients with relapsed or refractory multiple myeloma after at least four prior therapies.
The approval was based on the drug's response rate and durability of response, with ongoing studies required to confirm its clinical benefits, indicating a promising new option for patients with difficult-to-treat multiple myeloma.
Elranatamab: First Approval.Dhillon, S.[2023]
In the MagnetisMM-1 trial involving 88 patients with relapsed or refractory multiple myeloma, elranatamab demonstrated a significant overall response rate of 63.6%, with 38.2% of patients achieving a complete response or better, indicating its efficacy even in heavily pre-treated patients.
Elranatamab showed manageable safety with no dose-limiting toxicities during dose escalation, although some patients experienced cytopenias and cytokine release syndrome; the median progression-free survival was 11.8 months and overall survival was 21.2 months, suggesting promising durability of responses.
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.Bahlis, NJ., Costello, CL., Raje, NS., et al.[2023]
Elotuzumab, when combined with other treatments, significantly improved progression-free survival (PFS) by 14% and overall survival (OS) by 20% in multiple myeloma patients, based on a review of five randomized control trials involving 1,763 participants.
While Elotuzumab showed efficacy in relapsed/refractory multiple myeloma, it also increased the risk of serious adverse events, infections, and cardiac disorders, indicating a need for careful monitoring in patients receiving this treatment.
Safety and efficacy of Elotuzumab combination therapy for patients with multiple myeloma: A systematic review and meta-analysis.Noori, M., Fayyaz, F., Rezaei, N.[2023]

References

Elranatamab: First Approval. [2023]
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. [2023]
Safety and efficacy of Elotuzumab combination therapy for patients with multiple myeloma: A systematic review and meta-analysis. [2023]
Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case. [2023]
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. [2022]
FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma. [2018]
Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma. [2018]
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. [2023]
Elotuzumab for the treatment of multiple myeloma. [2022]